Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN Study.

Published online

Journal Article

Introduction: The Cure Glomerulonephropathy Network (CureGN) is a 66-center longitudinal observational study of patients with biopsy-confirmed minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, or IgA nephropathy (IgAN), including IgA vasculitis (IgAV). This study describes the clinical characteristics and treatment patterns in the IgA cohort, including comparisons between IgAN versus IgAV and adult versus pediatric patients. Methods: Patients with a diagnostic kidney biopsy within 5 years of screening were eligible to join CureGN. This is a descriptive analysis of clinical and treatment data collected at the time of enrollment. Results: A total of 667 patients (506 IgAN, 161 IgAV) constitute the IgAN/IgAV cohort (382 adults, 285 children). At biopsy, those with IgAV were younger (13.0 years vs. 29.6 years, P < 0.001), more frequently white (89.7% vs. 78.9%, P = 0.003), had a higher estimated glomerular filtration rate (103.5 vs. 70.6 ml/min per 1.73 m2, P < 0.001), and lower serum albumin (3.4 vs. 3.8 g/dl, P < 0.001) than those with IgAN. Adult and pediatric individuals with IgAV were more likely than those with IgAN to have been treated with immunosuppressive therapy at or prior to enrollment (79.5% vs. 54.0%, P < 0.001). Conclusion: This report highlights clinical differences between IgAV and IgAN and between children and adults with these diagnoses. We identified differences in treatment with immunosuppressive therapies by disease type. This description of baseline characteristics will serve as a foundation for future CureGN studies.

Full Text

Duke Authors

Cited Authors

  • Selewski, DT; Ambruzs, JM; Appel, GB; Bomback, AS; Matar, RB; Cai, Y; Cattran, DC; Chishti, AS; D'Agati, VD; D'Alessandri-Silva, CJ; Gbadegesin, RA; Hogan, JJ; Iragorri, S; Jennette, JC; Julian, BA; Khalid, M; Lafayette, RA; Liapis, H; Lugani, F; Mansfield, SA; Mason, S; Nachman, PH; Nast, CC; Nester, CM; Noone, DG; Novak, J; O'Shaughnessy, MM; Reich, HN; Rheault, MN; Rizk, DV; Saha, MK; Sanghani, NS; Sperati, CJ; Sreedharan, R; Srivastava, T; Swiatecka-Urban, A; Twombley, K; Vasylyeva, TL; Weaver, DJ; Yin, H; Zee, J; Falk, RJ; Gharavi, AG; Gillespie, BW; Gipson, DS; Greenbaum, LA; Holzman, LB; Kretzler, M; Robinson, BM; Smoyer, WE; Flessner, M; Guay-Woodford, LM; Kiryluk, K; CureGN Consortium,

Published Date

  • November 2018

Published In

Volume / Issue

  • 3 / 6

Start / End Page

  • 1373 - 1384

PubMed ID

  • 30450464

Pubmed Central ID

  • 30450464

Electronic International Standard Serial Number (EISSN)

  • 2468-0249

Digital Object Identifier (DOI)

  • 10.1016/j.ekir.2018.07.021

Language

  • eng

Conference Location

  • United States